 |
|
Antipsychotic Agents and Cardiometabolic Morbidity in Youth
Stefan P. Kruszewski, MD;
Richard P. Paczynski, MD
Arch Pediatr Adolesc Med. 2009;163(4):394-395.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The October issue of Archives included what we consider a landmark article by McIntyre and Jerrell.1 As clinicians involved in the evaluation of mentally ill youth, many of whom present for care taking multiple psychoactive medications for dubious indications, we are alarmed by the authors' finding that antipsychotic agents in particular are associated with serious cardiometabolic morbidity in children and adolescents, as they are in adults.2-3 Their findings are all the more impressive given the relatively high medical morbidity in the untreated control group, with whom the subjects taking antipsychotic agents were compared. In light of the aggressive off-label marketing of antipsychotic drugs to physicians involved in both state-managed and private health care programs for youth, it is particularly important that both mental health specialists and primary care physicians be aware of these data.
However, we would like to make a critical . . . [Full Text of this Article] AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Metabolic and Cardiovascular Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents
Roger S. McIntyre and Jeanette M. Jerrell
Arch Pediatr Adolesc Med. 2008;162(10):929-935.
ABSTRACT
| FULL TEXT
RELATED LETTER
Antipsychotic Agents and Cardiometabolic Morbidity in Youth—Reply
Roger S. McIntyre and Jeanette M. Jerrell
Arch Pediatr Adolesc Med. 2009;163(4):395.
EXTRACT
| FULL TEXT
|
